Blood cancer diagnostics can be defined as the wide range of screening & diagnosis tests associated with blood cancers such as lymphoma, leukemia, and myeloma.
Bone marrow examination, blood sample tests, complete blood count tests, flow cytometry, cupping therapy, and genetic testing are prominent procedures in the diagnosis of blood cancer.
An increase in the prevalence of oncological diseases and technological advancements in diagnostics are positively impacting the global blood cancer diagnostics market. Focus on detecting cancer at an early stage through molecular and RNA/DNA testing can widely improve the diagnosis.
As spending on healthcare witnesses a gradual increase in developing countries, the overall blood cancer diagnostics market is projected to grow at a steady rate during the forecast period 2017-2022. According to Fact.MR’s analysis, the global blood cancer diagnostics market is projected to grow at a steady CAGR during the forecast period.
Fact.MR’s report offers market analysis and forecast on the global blood cancer diagnostics market on the basis of test type. Liquid biopsy is another test type that remains widely used among end-users.
Studies have shown that liquid biopsy can overcome challenges related to intra- and inter-tumor heterogeneity.
The research was carried out at Harvard Medical School and Massachusetts General Hospital Cancer Center. The inclusion of liquid biopsy can help in identifying resistance alternations in patients with advanced cholangiocarcinoma.
On account of growing preference for liquid biopsy, this segment is projected to increase at a CAGR of over 10% through 2022.
According to the report, the CBC test segment type of the global blood cancer market is valued at nearly US$ 77 million in 2017. By 2022, this is projected to grow at a healthy rate.
The market in North America will remain lucrative for manufacturers throughout the forecast period. The CTC tests segment on the other hand, is anticipated to grow at a relatively higher CAGR than the CBC test segments.
Owing to the accuracy and convenience of blood testing protein test type, it is anticipated that more end-use sectors will continue to use this type of testing globally. Fact.MR estimates the global blood protein testing market to rake in significant revenues during the forecast period.
By end-users, hospital-associated labs account for a significant percentage of the global blood cancer diagnostics market. Valued at over US$ 136 million in 2017, the hospital-associated lab's segment is projected to surpass US$ 180 million in revenues by 2022.
Demand from the hospital-associated lab's segment is projected to grow at a steady CAGR during the forecast period.
Demand for blood cancer diagnostics is also significant from the independent diagnostic laboratories segment.
According to Fact.MR’s research, the independent diagnostics laboratories segment is projected to grow steadily through 2022. Cancer research institutes are also key end-user, and demand from this segment is projected to grow at healthy CAGR through 2022.
The key companies profiled in Fact.MR’s research include
- Abbott Laboratories
- Roche Holding A.G.
- Thermo Fisher Scientific Inc.
- Laboratory Corporation of America Holdings
- Luminex Corporation
- Myriad Genetics Inc.
- NanoString Technologies Inc
- NeoGenomics Laboratories Inc.
- Siemens AG
- Quest Diagnostics Incorporated
- Qiagen N.V.
- Agilent Technologies
- Biotheranostics Inc
- Almac Group Limited
- GeneNews Limited.
Overall, the global blood cancer diagnostics market is anticipated to witness steady growth through 2022. The market will continue to be influenced by regulatory policies and guidelines.
|Test Type||CBC Tests
Blood Protein Testing
Bone Marrow Biopsy
|End User||Hospital Associated Labs
Independent Diagnostic Laboratories
Cancer Research Institutes
(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)
Medical organizations as well as leaders in the global pharmaceuticals industry are stepping up their efforts towards development of profound diagnosis for blood cancer.
Rising number of deaths caused by blood cancer is taking a toll on governments as people are demanding precision diagnosis and a cure-all for this terminal disease. In a bid to adapt to the urban rat race, millions of consumers have adopted lifestyles that are stemming the occurrence of blood cancer.
For public administration authorities, compelling people to avoid such lifestyles is like challenging the status quo.
The burden of controlling the incidence of blood cancer gets passed on to hospitals & medical research organizations as they strive to develop novel diagnostic and therapeutic procedures.
The report on the global market for blood cancer diagnostics discusses such key factors that govern the economics of blood cancer diagnostics across the globe. Some of the key influences for the growth of global blood cancer diagnostics market include:
- rising presence of carcinogenic elements in common consumables
- surging exposure to toxic substances in factories & industrial settings
- lack of awareness related to causes, symptoms, and preventive measures for blood cancer
- high healthcare costs, deterring blood cancer patients from seeking optimum diagnosis
With growing incidence of blood cancer, the future generations will witness a more accessible, affordable, and diagnosis-associated treatment for blood cancer.
As blood cancer research organizations & societies struggle to develop effective medications in tight-budgeted capitals, governments are deploying initiatives that boost the awareness of blood cancer.
Need for Premeditated Blood Cancer Patient Compliance
Blood cancer patients are often riddled with confusing options for diagnosis. Choosing the right screening test can become a dilemma for the patient and his/her family.
Companies manufacturing medical instruments and devices for diagnosis of blood cancer are expected to mitigate such difficulties by facilitating a well-laid patient compliance regime.
The global market for blood cancer diagnostics is anticipated to witness significant impact from diagnosis-associated patient compliance trials. Positive attitudes of patients towards certain diagnosis alternatives is decisive in changing future undertakings.
Prominent diagnostic tools are likely to be replaced with their upgraded variants. The report has highlighted the influence of government undertakings in offering a better compliance for diagnosis of blood cancer patients.
Key players in the global blood cancer diagnostics market are collaborating with regional health ministries and medical administrators for gauging the impact of therapeutic diagnosis on blood cancer patients.
Such cooperative efforts are of paramount importance in the global blood cancer diagnostics market, where overlooking the plausible aftereffects of diagnostic procedures can cost lives.
Blood Cancer diagnostics market – Regional Overview & Competitive Backdrop
A comprehensive section on the regional analysis of global blood cancer diagnostics market is included in the report. North America, Europe, Japan, Asia-Pacific excluding Japan (APEJ), Latin America, and Middle East & Africa are key regions into which the expansion of global blood cancer diagnostics market is studied.
Developed markets with robust healthcare infrastructures are deemed lucrative for patients seeking diagnosis for blood cancer. On the other hand, higher resource availability, cheap wages, and lenient manufacturing regulations in developing regions attract the attention of manufacturers of blood cancer diagnosis instruments.
In the report, there is an elaborate section on the competitive landscape of global blood cancer diagnostics market. This part profiles key players in the global market, which includes leading manufacturers of diagnostic devices and related medical apparatus.
The scalability employed in profiling these players includes criteria such as the company’s contribution to global blood cancer diagnostics market revenues, recent mergers & acquisitions involving the company, and new product launches.
Through this report, companies can also understand the investment standpoint in the global blood cancer diagnostics market, which can be further inferred while taking insightful actions.
Fact.MR is committed to offer unbiased and independent market research solutions to its clients.
Each market report of Fact.MR is compiled after months of exhaustive research. We bank on a mix of tried-and-tested and innovative research methodologies to offer the most comprehensive and accurate information. Our main sources of research include,
- Primary research
- Secondary research
- Trade research
- Focused interviews
- Social media analysis
Need an Exclusive Report for your Unique Requirement?
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.